Bergqvist V, Holmgren J, Klintman D, Marsal J, et al. Real-world data on switching from intravenous to subcutaneous vedolizumab treatment in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2022 Apr 25. doi: 10.1111/apt.16927.
PMID: 35470449